INFORMAZIONI SU QUESTO EPISODIO
Sometimes hyperthyroidism is straightforward, and other times… management takes the long and winding road. In this Partner Podcast episode, Dr. Audrey Cook joins Dr. Beth to discuss the unmasking of chronic kidney disease following treatment of feline hyperthyroidism and review strategies for the monitoring and long-term management of cats with both conditions. Tune in for a practical framework for methimazole trials, the role of an FDA-approved oral methimazole solution, and treatment decisions in complex patients.
Sponsored by Virbac
Contact us:
Where to find us:
- Website: CliniciansBrief.com/Podcasts
- YouTube: Youtube.com/@clinicians_brief
- Facebook: Facebook.com/CliniciansBrief
- LinkedIn: LinkedIn.com/showcase/CliniciansBrief/
- X: @cliniciansbrief
- Instagram: @clinicians.brief
The Team:
- Beth Molleson, DVM - Host
- Taylor Argo- Producer, Sound Editing, & Project Manager, Brief Studio
IMPORTANT SAFETY INFORMATION: Felanorm® (methimazole) Oral Solution: As with all methimazole products, wear protective single use, impermeable (e.g., latex or nitrile) gloves when administering the solution. The most commonly reported side effects in cats are anorexia, vomiting, head/facial pruritus or edema, depression/lethargy, weight loss, anemia, elevated liver enzymes, skin lesions, elevated BUN, diarrhea, and thrombocytopenia. In some reported cases, the patients recovered after adverse reactions were recognized, the drug was withdrawn, and veterinary care was applied. Methimazole has anti-vitamin K activity and may induce bleeding diathesis without evidence of thrombocytopenia. Not for use in pregnant or lactating queens. Not for use in cats with primary renal or hepatic failure, autoimmune disease, or with hematological disorders (see the full prescribing information for additional details). For full prescribing information, contact VIRBAC at 1-800-338-3659, visit vet‑us.virbac.com or click to download.
